Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
January 31, 2023
- Takeda to Transfer MS Med Copaxone to Teva JV, 1st Patented Drug under 2020 Pact
January 30, 2023
- Estimated 21,528 Patients Given Xocova as of Jan. 22: Shionogi
January 30, 2023
- Lecanemab Application Accepted for Review in Europe; FY2023 Approval Eyed
January 30, 2023
- NanoCarrier to Shift Biz Model to mRNA Out-Licensing, Joins Forces with Axcelead
January 27, 2023
- Torii Acquires Japan Rights for Nogra Pharma’s Acne Drug
January 27, 2023
- Enhertu Wins EU Approval for HER2 Low Breast Cancer
January 27, 2023
- Shipments of All 6 Argatroban Products Suspended or Restricted in Japan
January 26, 2023
- Multifunctional Peptide Conjugate Meets Criteria in Joint Research: PeptiDream/Santen
January 26, 2023
- Ono/KSQ Therapeutics Tie Up for Cancer Drug Discovery
January 26, 2023
- Takeda Gets Rights to Hutchmed’s Colorectal Cancer Med Outside China
January 25, 2023
- Astellas to Divest Antifungal Micafungin to Sandoz for Up to US$75 Million Upfront
January 25, 2023
- Moderna, NCGM Ink MOU to Push mRNA-Based Healthcare
January 24, 2023
- J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
January 24, 2023
- Alzheimer’s Drug Leqembi Now Available in US: Eisai/Biogen
January 24, 2023
- US FDA Lifts Clinical Hold of Astellas’ Pompe Gene Therapy
January 23, 2023
- Acoalan’s PIII Trial for Preeclampsia Due to Complete in July: Kyowa Kirin
January 23, 2023
- Meiji’s Stelara Biosimilar Shows Therapeutic Equivalence; Filing Eyed in 2023
January 23, 2023
- CSL Behring Launches App to Manage Hizentra Treatment Records
January 20, 2023
- Eisai Starts Stand-Alone Biz Operations in Israel
January 20, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…